NeoGenomics Posts 6-Cent Q3 Loss Per Share
NEO has more than doubled off its 52-week low of $7.065.
Summary
NeoGenomics reported a third-quarter loss of $7.55 million, or 6 cents per share, on revenue of $209.3 million, up 11% from a year earlier with the loss narrowing. That revenue compares with an IBES estimate of USD 207.3 million. The results follow the October 5 8-K, which disclosed preliminary Q3 revenue of about $200 million alongside the CEO succession plan naming Warren Stone to take over January 4, 2027. Shares already fell more than 12% on October 6 after the succession announcement, so the market has been sensitive to this name. Watch the full Q3 release and any guidance update for whether the loss reflects one-time items or a margin problem.
At the time of this announcement, NEO was trading at $18.00 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.3B. The 52-week trading range was $7.07 to $20.15. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Dow Jones Newswires.